Search Result

Results for "

prostate diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Adrenergic Receptor (4) Akt (1) Aldehyde Dehydrogenase (ALDH) (2) Androgen Receptor (2) Apoptosis (8) Bacterial (3) Biochemical Assay Reagents (1) Cytochrome P450 (1) Drug Metabolite (1) Epigenetic Reader Domain (1) Fatty Acid Synthase (FASN) (1) Fungal (1) GnRH Receptor (2) Histone Acetyltransferase (1) Histone Demethylase (1) Histone Methyltransferase (2) HSV (1) Integrin (1) Isotope-Labeled Compounds (1) MMP (1) NF-κB (2) NO Synthase (1) p38 MAPK (1) Phosphodiesterase (PDE) (1) PROTACs (1) Pyruvate Kinase (1) TRP Channel (1) Virus Protease (1)
By Research Areas:	Cancer (23) Cardiovascular Disease (8) Endocrinology (7) Infection (5) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (2)

By Targets:

Adenosine Receptor (1)

Adrenergic Receptor (4)

Akt (1)

Aldehyde Dehydrogenase (ALDH) (2)

Androgen Receptor (2)

Apoptosis (8)

Bacterial (3)

Biochemical Assay Reagents (1)

Cytochrome P450 (1)

Drug Metabolite (1)

Epigenetic Reader Domain (1)

Fatty Acid Synthase (FASN) (1)

Fungal (1)

GnRH Receptor (2)

Histone Acetyltransferase (1)

Histone Demethylase (1)

Histone Methyltransferase (2)

HSV (1)

Integrin (1)

Isotope-Labeled Compounds (1)

MMP (1)

NF-κB (2)

NO Synthase (1)

p38 MAPK (1)

Phosphodiesterase (PDE) (1)

PROTACs (1)

Pyruvate Kinase (1)

TRP Channel (1)

Virus Protease (1)

By Research Areas:

Cancer (23)

Cardiovascular Disease (8)

Endocrinology (7)

Infection (5)

Inflammation/Immunology (7)

Metabolic Disease (1)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: PSMA

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2908

Atraric acid Methyl atrarate	Androgen Receptor NO Synthase p38 MAPK NF-κB	Inflammation/Immunology Cancer
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases .

HY-144669

ALDH1A3-IN-2	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH1A3-IN-2 (Compound 15) is a potent inhibitor of ALDH1A3 with an IC₅₀ of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH1A3-IN-2 has the potential for the research of cancer diseases .

HY-122605

TRPM4-IN-1 CBA	TRP Channel	Cardiovascular Disease Cancer
TRPM4-IN-1 (CBA) is a potent and selective inhibitor of the cation channel TRPM4, with an IC₅₀ of 1.5 μM. TRPM4-IN-1 can be used for the research of cardiac diseases and prostate cancer .

HY-144671

ALDH3A1-IN-2	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH3A1-IN-2 (Compound 19) is a potent inhibitor of ALDH3A1 with an IC₅₀ of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH3A1-IN-2 has the potential for the research of cancer diseases .

HY-101826

ER21355

Phosphodiesterase (PDE) Cancer

ER21355 is an inhibitor of phosphodiesterase 5 (PDE5), used for treatment of prostatic diseases.

ER21355	Phosphodiesterase (PDE)	Cancer
ER21355 is an inhibitor of phosphodiesterase 5 (PDE5), used for treatment of prostatic diseases.

HY-B0900

Anethole 1 Publications Verification Anise camphor; p-Propenylanisole; Isoestragole	Apoptosis Fungal Bacterial MMP NF-κB	Infection Neurological Disease Inflammation/Immunology Cancer
Anethole is a type of orally active aromatic compound that is widely found in nature and used as a flavoring agent. Anethole possesses anticancer, anti-inflammatory, antioxidant, antibacterial, antifungal, anesthetic, estrogenic, central nervous system depressant, hypnotic, insecticidal, and gastroprotective effects. Anethole can be used in the study of oxidative stress-related skin diseases and prostate cancer .

HY-110154

NSC636819	Histone Demethylase	Cancer
NSC636819 is a competitive and selective inhibitor of KDM4A/KDM4B. KDM4A/KDM4B are potential progression factors for prostate cancer. NSC636819 has the potential for the research of cancer diseases, especially prostate cancer .

HY-112549

5-oxo-ETE 5-KETE	Others	Cardiovascular Disease Inflammation/Immunology Cancer
5-oxo-ETE is a potent chemoattractant for eosinophils. 5-oxo-ETE inhibits selenium-induced apoptosis in prostate cancer cells. 5-oxo-ETE can be used in research into asthma, allergic diseases, cancer and cardiovascular disease .

HY-145388

AU-15330 3 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide. AU-15330 induces disease remission in castration-resistant prostate cancer (CRPC) models without toxicity .

HY-152241

DS-9300	Histone Acetyltransferase	Cancer
DS-9300 is a potent, orally active, selective EP300/CBP HAT inhibitor with an IC₅₀ value of 28 nM. DS-9300 has anticancer activity and can be used in prostate cancer disease research .

HY-19702

PKR activator 3	Pyruvate Kinase	Metabolic Disease Inflammation/Immunology Cancer
PKR activator 3 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160. PKR activator 3 can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia .

HY-156530

CYP11A1-IN-1	Cytochrome P450	Endocrinology
CYP11A1-IN-1 (compound 30) is an inhibitor of CYP11A1, with IC₅₀ value of 201-2000 nM. CYP11A1-IN-1 can be used for research in steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer .

HY-N0288

Lycorine Maximum Cited Publications 12 Publications Verification	Fatty Acid Synthase (FASN) Virus Protease Bacterial Apoptosis	Inflammation/Immunology Cancer
Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a K_d value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription . Lycorine is also a melanoma vasculogenic inhibitor . Lycorine can be used for the study of prostate cancer and metabolic diseases .

HY-110112

BTT-3033	Integrin Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
BTT-3033 is an orally active conformation-selective inhibitor of α2β1 (EC50: 130 nM) by binding to the α2I domain. BTT-3033 inhibits platelet binding to collagen Ⅰ and cell proliferation, and induces cell apoptosis. BTT-3033 can be used in the research of prostate cancer, inflammation and cardiovascular disease .

HY-113289

Brassicasterol	Akt Androgen Receptor Bacterial Drug Metabolite HSV	Infection Cardiovascular Disease Neurological Disease Cancer
Brassicasterol is a metabolite of Ergosterol and has cardiovascular protective effects. Brassicasterol exerts anticancer effects in prostate cancer through dual targeting of AKT and androgen receptor signaling pathways. Brassicasterol inhibits HSV-1 (IC₅₀=1.2 μM) and Mycobacterium tuberculosis. Brassicasterol also inhibits sterol δ 24-reductase, slowing the progression of atherosclerosis. Brassicasterol is also a cerebrospinal fluid biomarker for Alzheimer's disease .

HY-16474

Relugolix TAK-385	GnRH Receptor	Endocrinology Cancer
Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC₅₀=0.33 nM) and monkey receptor (IC₅₀=0.32 nM) compared with TAK-013 (HY-100209) . Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al .

HY-144094

EZH2-IN-9	Histone Methyltransferase	Cancer
EZH2-IN-9 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-9 has the potential for the research of cancer diseases (extracted from patent WO2021180235A1, compound 17) .

HY-143616

EZH2-IN-7	Histone Methyltransferase	Cancer
EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259) .

HY-16474S

Relugolix-d6 TAK-385-d₆	Isotope-Labeled Compounds GnRH Receptor	Endocrinology Cancer
Relugolix-d₆ is deuterium labeled Relugolix. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209)[1]. Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al[2].

HY-13591

Piclidenoson 3 Publications Verification IB-MECA; CF-101	Adenosine Receptor Apoptosis	Inflammation/Immunology Cancer
Piclidenoson (IB-MECA) is a first-in-class, orally active and selective A3 adenosine receptor (A3AR) agonist. Piclidenoson exhibits antiproliferative effect and induces apoptosis in different cancer cell types like melanoma, leukemia. Piclidenoson can be used for the research of autoimmune inflammatory diseases and COVID-19 .

HY-17503B

Metoprolol tartrate	Adrenergic Receptor Apoptosis	Infection Cardiovascular Disease Endocrinology Cancer
Metoprolol tartrate is an orally active, selective β1-adrenoceptor antagonist. Metoprolol tartrate shows anti-inflammation, antitumor and anti-angiogenic properties .

HY-17503A

Metoprolol succinate 5+ Cited Publications	Adrenergic Receptor Apoptosis	Cardiovascular Disease Endocrinology Cancer
Metoprolol succinate is an orally active, selective β1-adrenoceptor antagonist. Metoprolol succinate shows anti-inflammation, antitumor and anti-angiogenic properties .

HY-17503

Metoprolol 5+ Cited Publications	Adrenergic Receptor Apoptosis	Infection Cardiovascular Disease Endocrinology Cancer
Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties .

HY-17503C

Metoprolol fumarate CGP 2175C; Lopressor OROS	Adrenergic Receptor Apoptosis	Infection Cardiovascular Disease Endocrinology Cancer
Metoprolol fumarate (CGP 2175C) is an orally active, selective β1-adrenoceptor antagonist. Metoprolol fumarate shows anti-inflammation, antitumor and anti-angiogenic properties .

HY-131384

8,11,14-Eicosatriynoic acid 8,11,14-Icosatriynoic acid	Biochemical Assay Reagents	Others
8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization . 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Anti-Cancer Natural Product Library	1582 compounds
With features of enormous scaffold diversity and structural complexity, natural products (NPs) are the main sources of lead compounds and new drugs and play a highly significant role in the drug discovery and development process, especially for cancer and infectious diseases. A large number of natural products have been proven to have potential anti-tumor effects, mainly from plants, animals, Marine organisms and microorganisms. At present, derived than 60% of anti-tumor drugs come from natural sources, and they are widely used in breast, prostate and colon cancers. MCE offers a unique collection of 1582 natural products with validated anti-cancer activity. MCE anti-cancer natural product library is a useful tool for anti-tumor drugs screening and other related research.

8,11,14-Eicosatriynoic acid 8,11,14-Icosatriynoic acid	Biochemical Assay Reagents
8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization . 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2908

Atraric acid Methyl atrarate	Structural Classification Microorganisms Classification of Application Fields Phenols Essence, Fragrance Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Cancer	Androgen Receptor NO Synthase p38 MAPK NF-κB
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases .

HY-B0900

Anethole 1 Publications Verification Anise camphor; p-Propenylanisole; Isoestragole	Structural Classification Classification of Application Fields Callicarpa maingayi King & Gamble Source classification Plants Microorganisms Simple Phenylpropanols Leguminosae Phenylpropanoids Umbelliferae Glycyrrhiza uralensis Fisch. Disease Research Fields Cancer	Apoptosis Fungal Bacterial MMP NF-κB
Anethole is a type of orally active aromatic compound that is widely found in nature and used as a flavoring agent. Anethole possesses anticancer, anti-inflammatory, antioxidant, antibacterial, antifungal, anesthetic, estrogenic, central nervous system depressant, hypnotic, insecticidal, and gastroprotective effects. Anethole can be used in the study of oxidative stress-related skin diseases and prostate cancer .

HY-N0288

Lycorine Maximum Cited Publications 12 Publications Verification	Alkaloids Structural Classification other families Pyrrole Alkaloids Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Amaryllidaceae	Fatty Acid Synthase (FASN) Virus Protease Bacterial Apoptosis
Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a K_d value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription . Lycorine is also a melanoma vasculogenic inhibitor . Lycorine can be used for the study of prostate cancer and metabolic diseases .

HY-113289

Brassicasterol	Infection Classification of Application Fields Animals Source classification Disease Research Fields Steroids Cancer	Akt Androgen Receptor Bacterial Drug Metabolite HSV
Brassicasterol is a metabolite of Ergosterol and has cardiovascular protective effects. Brassicasterol exerts anticancer effects in prostate cancer through dual targeting of AKT and androgen receptor signaling pathways. Brassicasterol inhibits HSV-1 (IC₅₀=1.2 μM) and Mycobacterium tuberculosis. Brassicasterol also inhibits sterol δ 24-reductase, slowing the progression of atherosclerosis. Brassicasterol is also a cerebrospinal fluid biomarker for Alzheimer's disease .

HY-17503

Metoprolol 5+ Cited Publications	Classification of Application Fields Disease Research Fields Endocrinology	Adrenergic Receptor Apoptosis
Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties .

Cat. No.	Product Name	Chemical Structure

HY-16474S

Relugolix-d6
Relugolix-d₆ is deuterium labeled Relugolix. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209)[1]. Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al[2].

Relugolix-d6

Relugolix-d₆ is deuterium labeled Relugolix. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209)[1]. Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

prostate diseases

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Natural
Products